19-11120381-T-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000527.5(LDLR):c.1999T>C(p.Cys667Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000031 in 1,614,014 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C667F) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.1999T>C | p.Cys667Arg | missense_variant | Exon 14 of 18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152156Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251398Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135892
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461858Hom.: 0 Cov.: 35 AF XY: 0.00000138 AC XY: 1AN XY: 727228
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152156Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74342
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:10
- -
Disrupt disulfide bridge between Cys667 and Cys681. -
- -
- -
subject mutated among 2600 FH index cases screened = 1/software prediction damaging -
The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). It is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported. The variant has been reported to co-segregate with the disease in at least one similarly affected relative/individual in the same family or similarly affected unrelated family (3billion dataset). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.99; 3Cnet: 1.00). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000252163). Different missense changes at the same codon (p.Cys667Phe, p.Cys667Ser, p.Cys667Trp, p.Cys667Tyr) have been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000003689 , VCV000252162 , VCV000252165 , VCV000252168). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -
This missense variant (also known as p.Cys646Arg in the mature protein) replaces cysteine with arginine at codon 667 in the EGF-like repeat C of the LDLR protein. This variant alters a conserved cysteine residue that is critical for proper protein folding and function (PMID: 2088165, 6091915, 15952897). Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This LDLR variant has been reported in over 10 heterozygous individuals affected with familial hypercholesterolemia (PMID: 17765246, 21310417, 22698793, 23064986, 28895539, 34037665). This variant has also been observed in homozygous state in six individuals affected with severe homozygous familial hypercholesterolemia in one large family, a phenotype expected of having two deleterious LDLR variants (PMID: 9412789). It has been shown that this variant segregates with disease in multiple affected individuals in one large family (PMID: 9412789). This variant has also been reported in an individual affected with early-onset myocardial infarction (PMID: 25487149, 27050191). This variant has been identified in 1/251398 chromosomes in the general population by the Genome Aggregation Database (gnomAD). A different variant affecting the same codon, p.Cys667Tyr, is considered to be disease-causing (ClinVar variation ID: 3689), suggesting that cysteine at this position is important for LDLR protein function. Based on the available evidence, this variant is classified as Pathogenic. -
- -
- -
0/200 non-FH alleles -
not provided Pathogenic:3
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28895539, 25487149, 21310417, 22698793, 27824480, 30415195, 24507775, 17765246, 23064986, 9412789, 33740630, 34037665) -
- -
The LDLR c.1999T>C; p.Cys667Arg variant (rs150021927) is reported in the literature in more than ten individuals affected with high LDL-C (Lange, 2014, Sturm 2021). Moreover, this variant has been identified as the only co-segregating allele within a large familial hypercholesterolemia family based on homozygosity (Vergopoulos,1997). This variant is also reported in ClinVar (Variation ID: 334184). This variant is only observed on one allele (1/251398 alleles) in the Genome Aggregation Database, indicating it is not a common polymorphism. The cysteine at codon 667 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.987). Based on available information, this variant is considered to be likely pathogenic. -
Familial hypercholesterolemia Pathogenic:1
This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 667 of the LDLR protein (p.Cys667Arg). This variant is present in population databases (rs150021927, gnomAD 0.003%). This missense change has been observed in individuals with familial hypercholesterolemia (PMID: 9412789, 17765246, 21310417, 23064986, 27824480). It has also been observed to segregate with disease in related individuals. This variant is also known as p.Cys646Arg. ClinVar contains an entry for this variant (Variation ID: 252163). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt LDLR protein function with a positive predictive value of 95%. This variant affects a cysteine residue located within an LDLRA or epidermal-growth-factor (EGF)-like domains of the LDLR protein. Cysteine residues in these domains have been shown to be involved in the formation of disulfide bridges, which are critical for protein structure and stability (PMID: 7548065, 7603991, 7979249). In addition, missense substitutions within the LDLRA and EGF-like domains affecting cysteine residues are overrepresented among patients with hypercholesterolemia (PMID: 18325082). This variant disrupts the p.Cys667 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been observed in individuals with LDLR-related conditions (PMID: 9727746, 11313767, 15701167, 18263977, 23375686), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at